BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2558-2567

  Gabellini, Chiara ^a   De Luca, Teresa ^a   Trisciuoglio, Daniela ^a   Desideri, Marianna ^a   Di Martile, Marta ^a   Passeri, Daniela ^b   Candiloro, Antonio ^a   Biffoni, Mauro ^c   Rizzo, Maria Giulia ^a   Orlandi, Augusto ^b   Del Bufalo, Donatella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL 2; VASCULOTROPIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS POTENTIAL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANOXIA; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MELANOMA; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84886995034     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt242     Document Type: Article

References (41)

1. Kelly,P.N.et al. (2011) The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ., 18, 1414-1424.
2. Akao,Y.et al. (1994) Multiple subcellular localization of bcl-2: detection in nuclear outer membrane, endoplasmic reticulum membrane, and mitochondrial membranes. Cancer Res., 54, 2468-2471.
3. Del Bufalo,D. et al. (1997) Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J., 11, 947-953.
4. Ricca,A.et al. (2000) bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int. J. Cancer, 86, 188-196.
5. Trisciuoglio,D.et al. (2005) Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J. Cell. Physiol., 205, 414-421.
6. Basolo,F.et al. (1999) Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl-2 gene. Int. J. Cancer, 81, 956-962.
7. Zhu,C.J.et al. (2003) Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells. J. Neurosci. Res., 74, 60-66.
8. Biroccio,A.et al. (2000) Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J., 14, 652-660.
9. Fernandez,A.et al. (2001) Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J. Natl Cancer Inst., 93, 208-213.
10. Iervolino,A.et al. (2002) Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J., 16, 1453-1455.
11. Trisciuoglio,D.et al. (2005) Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol. Biol. Cell, 16, 4153-4162.
12. Trisciuoglio,D.et al. (2010) Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One, 5, e11772.
13. Trisciuoglio,D.et al. (2011) Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death Differ., 18, 1024-1035.
14. Trisciuoglio,D.et al. (2013) Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth. Neoplasia, 15, 315-327.
15. Giorgini,S.et al. (2007) Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol. Cancer Res., 5, 761-771.
16. Del Bufalo,D. et al. (1998) N-methylformamide induces changes on adhesive properties and lung-colonizing potential of M14 melanoma cells. Br. J. Cancer, 77, 210-215.
17. Cantara,S.et al. (2004) Exogenous BH4/Bcl-2 peptide reverts coronary endothelial cell apoptosis induced by oxidative stress. J. Vasc. Res., 41, 202-207.
18. Wang,N.S.et al. (2001) Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J. Biol. Chem., 276, 44117-44128.
19. de Moissac,D. et al. (1999) Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. J. Biol. Chem., 274, 29505-29509.
20. Karl,E.et al. (2005) Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res., 65, 5063-5069.
21. Kaneko,T.et al. (2007) Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res., 67, 9685-9693.
22. Sakai,Y.et al. (2009) Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate, 69, 459-470.
23. Liu,Y.V.et al. (2007) Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization. J. Biol. Chem., 282, 37064-37073.
24. Hoetelmans,R.W.et al. (2003) The role of various Bcl-2 domains in the anti-proliferative effect and modulation of cellular glutathione levels: a prominent role for the BH4 domain. Cell Prolif., 36, 35-44.
25. Jin,Z.et al. (2006) Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J. Biol. Chem., 281, 14446-14456.
26. Wang,Q.et al. (2008) Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol. Cell, 29, 488-498.
27. Doumanis,J.et al. (2007) Molecular determinants of the subcellular localization of the Drosophila Bcl-2 homologues DEBCL and BUFFY. Cell Death Differ., 14, 907-915.
28. Kaufmann,T.et al. (2003) Characterization of the signal that directs Bclx(L), but not Bcl-2, to the mitochondrial outer membrane. J. Cell Biol., 160, 53-64.
29. Bogner,C.et al. (2010) Apoptosis: embedded in membranes. Curr. Opin. Cell Biol., 22, 845-851.
30. Portier,B.P.et al. (2006) Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. J. Biol. Chem., 281, 40493-40502.
31. Hour,T.C.et al. (2000) Suppression of transcription factor NF-kappaB activity by Bcl-2 protein in NIH3T3 cells: implication of a novel NF-kappaB p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2. Eur. J. Cell Biol., 79, 121-129.
32. Zhu,C.et al. (2010) Nuclear translocation and calpain-dependent reduction of Bcl-2 after neonatal cerebral hypoxia-ischemia. Brain. Behav. Immun., 24, 822-830.
33. de Jong,D. et al. (1994) Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res., 54, 256-260.
34. Lindenboim,L.et al. (2010) Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L). Cell Death Differ., 17, 346-359.
35. Strasser,C.et al. (2012) Regulation of nuclear envelope permeability in cell death and survival. Nucleus, 3, 540-551.
36. Depping,R.et al. (2008) Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway. Biochim. Biophys. Acta, 1783, 394-404.
37. Chachami,G.et al. (2009) Transport of hypoxia-inducible factor HIF-1alpha into the nucleus involves importins 4 and 7. Biochem. Biophys. Res. Commun., 390, 235-240.
38. Beham,A.et al. (1997) Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene, 15, 2767-2772.
39. Sun,T.et al. (2011) Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology, 54, 1690-1706.
40. Lee,S.S.et al. (1998) Nuclear overexpression of bcl-2 oncoprotein during the progression of human stomach cancer. J. Korean Med. Sci., 13, 153-158.
41. Zhao,N.et al. (2012) Coexpression of Bcl-2 with epithelial-mesenchymal transition regulators is a prognostic indicator in hepatocellular carcinoma. Med. Oncol., 29, 2780-2792.